CAS: 63435-16-5; Methyl 4-Amino-3-Hydroxybenzoate

上下游产品

4-氨基-3-羟基苯甲酸 4-Aminosalicylic Acid 2374-03-0
3-羟基-4-硝基苯甲酸甲酯 Methyl 3-Hydroxy-4-Nitrobenzoate 713-52-0
3-羟基-4-硝基苯甲酸 3-Hydroxy-4-Nitro-Benzoic Acid 619-14-7

3-羟基-4-硝基苯甲酸甲酯置于palladium On Carbon,氢气体系中,用 乙醇 作为反应溶剂,化学反应生成 4-氨基-3-羟基苯甲酸甲酯
参考文献:Sb-334867 的二芳基脲类似物作为食欲素 1 受体拮抗剂
标题:Sb-334867 的二芳基脲类似物作为食欲素 1 受体拮抗剂
摘要:作为我们开发 Ox1-Cb1 二价配体计划的一部分,我们需要更好地了解食欲素拮抗剂的基本构效关系 (Sar).合成了一系列 Sb-334867 类似物,并在钙动员测定中进行了评估.sar 结果表明,2-甲基苯并恶唑部分可以被双取代的 4-氨基苯基取代而不会失去活性,并且缺电子系统通常在 1,5-萘啶部分用于 Ox1 拮抗剂活性.特别是,较大的潜在接头如正己基的取代提供了化合物33与先导化合物 Sb-334867 相比,对 Ox1 受体具有同等活性.这些化合物在开发靶向orexin-1受体及其潜在异源二聚体的配体方面应该具有价值.
DOI:10.1016/j.Bmcl.2011.03.048

专利信息

专利号:US-10005720-B2
优先权日:2013-04-05
标题:Compounds useful for the treatment of metabolic disorders and synthesis of the same
发明人：SEXTON JONATHAN Z; BRENMAN JAY E; MUSSO DAVID L
权利人:NORTH CAROLINA CENTRAL UNIV; UNIV NORTH CAROLINA CHAPEL HILL
摘要:The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.

专利号:US-7067554-B2
优先权日:2000-05-30
标 题 :Method for the synthesis of compounds of formula I and their uses thereof
发明人：MJALLI ADNAN M M; GOPALASWAMY RAMESH; AVOR KWASI A; WYSONG CHRISTOPHER L; ANDREW PATRON
权利人:TRANSTECH PHARMA INC
摘要:This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, β-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.

专利号:US-6368831-B1
优先权日:1998-06-29
标题 :Treatment of hyperproliferative disorders
发明人：MAURER BARRY J; REYNOLDS C PATRICK
权利人:LOS ANGELES CHILDRENS HOSPITAL
摘要:A method of treating a hyperproliferative disorder in a subject in need of such treatment, comprising administering to said subject, in combination, a treatment effective amount of: (a) a ceramide-generating retinoid such as fenretinide or a pharmaceutically acceptable salt thereof; and (b) at least one (and in certain embodiments at least two) ceramide degredation inhibitor, such as compounds selected from the group consisting of (i) glucosylceramide synthesis inhibitors and/or 1-acylceramide synthesis inhibitors, (ii) sphingosine-1-phosphate synthesis inhibitors, and (iii) protein kinase C inhibitors. A preferred glucosyl ceramide synthesis inhibitor is 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol. A preferred sphingosine-1-phosphate synthesis inhibitor is D-erythro-N,N-dimethylsphingosine. A preferred protein kinase C inhibitor is L-threo-dihydrosphingosine.

专利号:US-6352844-B1
优先权日:1998-06-29
标题:Treatment of hyperproliferative disorders
发明人：MAURER BARRY J; CABOT MYLES; REYNOLDS C PATRICK
权利人:LOS ANGELES CHILDRENS HOSPITAL; WAYNE JOHN CANCER INST
摘要:A method of treating a hyperproliferative disorder in a subject in need of such treatment, comprising administering to said subject, in combination, a treatment effective amount of: (a) a ceramide-generating retinoid such as fenretinide or a pharmaceutically acceptable salt thereof; and (b) at least one (and in certain embodiments at least two) ceramide degredation inhibitor, such as compounds selected from the group consisting of (i) glucosylceramide synthesis inhibitors, (ii) sphingosine-1-phosphate synthesis inhibitors, and (iii) protein kinase C inhibitors. A preferred glucosyl ceramide synthesis inhibitor is 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol. A preferred sphingosine-1-phosphate synthesis inhibitor is D-erythro-N,N-dimethylsphingosine. A preferred protein kinase C inhibitor is L-threo-dihydrosphingosine.

专利号:US-2018370905-A1
优先权日:2013-04-05
标题:Compounds Useful for the Treatment of Metabolic Disorders and Synthesis of the Same

专利号:AU-2005200425-A1
优先权日:2000-05-30
标题 :A method for the synthesis of compounds of formula 1 and their uses thereof